Published in J Clin Oncol on October 01, 1994
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer (2002) 1.22
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res (2011) 0.83
Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol Clin Oncol (2012) 0.83
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol (2012) 0.81
Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry (1996) 0.81
Factors responsible for long-term survival in metastatic breast cancer. World J Surg Oncol (2014) 0.80
Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Br J Cancer (1996) 0.80
A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat (2013) 0.78
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol (2005) 0.77
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. Br J Cancer (1995) 0.77
Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor. Br J Cancer (1998) 0.76
Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care (Basel) (2010) 0.75
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Oncologist (2012) 0.75
Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. J Breast Cancer (2011) 0.75
Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer. Contemp Oncol (Pozn) (2013) 0.75
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma. Invest New Drugs (2004) 0.75
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. Lancet (1999) 12.51
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol (1994) 3.48
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage (1999) 2.52
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol (1997) 1.94
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest (1997) 1.61
Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am (2006) 1.54
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup Environ Med (2005) 1.47
Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations. Int J Biol Markers (1998) 1.45
Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer (1993) 1.44
Should the skin prick test to horse be included in the standard panel for the diagnosis of respiratory allergy? J Investig Allergol Clin Immunol (2009) 1.42
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res (1995) 1.39
Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer (1995) 1.35
Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers (2004) 1.35
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol (1999) 1.27
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer (2004) 1.26
High expression of beta-adrenergic receptor kinase in human peripheral blood leukocytes. Isoproterenol and platelet activating factor can induce kinase translocation. J Biol Chem (1992) 1.25
Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J (1998) 1.20
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer (2004) 1.20
Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol (1996) 1.15
Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol (1992) 1.14
The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol (2013) 1.12
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res (1999) 1.12
Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer (1996) 1.11
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol (2010) 1.10
Urticaria and urticaria related skin condition/disease in children. Eur Ann Allergy Clin Immunol (2008) 1.08
Dependence of fibroblast autofluorescence properties on normal and transformed conditions. Role of the metabolic activity. Photochem Photobiol (1999) 1.08
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol (2007) 1.06
Molecular analysis of human beta-arrestin-1: cloning, tissue distribution, and regulation of expression. Identification of two isoforms generated by alternative splicing. J Biol Chem (1993) 1.06
Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol (1989) 1.05
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer (1996) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol (2012) 1.02
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer (1997) 1.02
A second hysterosalpingography reduces the use of selective technique for treatment of a proximal tubal obstruction. Fertil Steril (2000) 1.02
c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. Eur J Cancer (1994) 1.01
Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer (1998) 1.01
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer (1999) 1.00
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol (2012) 0.99
Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol (2012) 0.98
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol (2006) 0.97
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer (2001) 0.96
Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study. Breast Cancer Res Treat (1995) 0.95
Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer (1991) 0.95
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer (1999) 0.95
Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online (2008) 0.95
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol (2009) 0.95
Early acute necrosis, delayed apoptosis and cytoskeletal breakdown in cultured cerebellar granule neurons exposed to methylmercury. J Neurosci Res (2000) 0.93
A single-step staining procedure for the detection and sorting of unfixed apoptotic thymocytes. Eur J Histochem (1993) 0.93
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer (2000) 0.92
Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis (2012) 0.92
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol (1996) 0.91
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology (1996) 0.91
Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori (1988) 0.91
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J Biol Regul Homeost Agents (2000) 0.91
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol (2002) 0.90
The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol (1999) 0.90
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology (1991) 0.90
The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. Eur J Surg Oncol (2011) 0.90
Radiation dose exposure during cardiac and peripheral arteries catheterisation. Int J Cardiol (2005) 0.90
Blood loss following noncomplicated transvaginal oocyte retrieval for in vitro fertilization. Fertil Steril (2001) 0.90
Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol. Arzneimittelforschung (1970) 0.90
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer (1995) 0.89
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer (1997) 0.89
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2001) 0.89
Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. Breast Cancer Res Treat (1999) 0.89
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer (1997) 0.89
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer (2000) 0.89
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer (1992) 0.89
The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer (1990) 0.88
Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats. Eur J Histochem (2012) 0.88
Ocular metastases from breast carcinoma: A multicentric retrospective study. Oncol Rep (2000) 0.88
Hysteroscopic permanent tubal sterilization using a nitinol-dacron intratubal device without anaesthesia in the outpatient setting: procedure feasibility and effectiveness. Hum Reprod (2005) 0.87
Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol (2009) 0.87
[Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma]. Arch Ital Urol Androl (1997) 0.87
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer (1994) 0.87
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer (1998) 0.87
Evidence for altered opioid activity in patients with cancer. Br J Cancer (1987) 0.86
Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer. Breast Cancer Res Treat (2000) 0.86
Spontaneous apoptosis of thymocytes is uncoupled with progression through the cell cycle. Exp Cell Res (1996) 0.86
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology (1990) 0.86
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer. Tumori (1986) 0.86
Different patterns of apoptosis in response to cisplatin in B50 neuroblastoma rat cells. Histol Histopathol (2011) 0.85
Development of an interactive learning tool for teaching rheumatology--a simulated clinical case studies program. Rheumatology (Oxford) (2006) 0.85
Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. Ann Oncol (2008) 0.85